NERV Minerva Neurosciences Inc

Price (delayed)

$5.1

Market cap

$237.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$37.03

Enterprise value

$264.84M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.

Highlights
The company's quick ratio has surged by 95% YoY but it has shrunk by 52% QoQ
Minerva Neurosciences's equity has shrunk by 80% QoQ
The company's net income fell by 41% QoQ

Key stats

What are the main financial stats of NERV

NERV stock price

How has the Minerva Neurosciences stock price performed over time
Intraday
-0.97%
1 week
24.09%
1 month
7.37%
1 year
194.81%
YTD
26.87%
QTD
-8.11%

Financial performance

How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.87M
Net income
-$415.07M
Gross margin
N/A
Net margin
N/A
NERV's operating income has dropped by 85% since the previous quarter and by 46% year-on-year
The company's net income fell by 41% QoQ

Price vs fundamentals

How does NERV's price correlate with its fundamentals

Growth

What is Minerva Neurosciences's growth rate over time

Valuation

What is Minerva Neurosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 7% since the previous quarter
Minerva Neurosciences's equity has shrunk by 80% QoQ

Efficiency

How efficient is Minerva Neurosciences business performance
The return on invested capital has declined by 19% since the previous quarter
Minerva Neurosciences's return on assets has decreased by 7% QoQ

Dividends

What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NERV.

Financial health

How did Minerva Neurosciences financials performed over time
The total assets is 73% less than the total liabilities
The total assets has soared by 187% YoY but it has contracted by 4% from the previous quarter
The company's quick ratio has surged by 95% YoY but it has shrunk by 52% QoQ
The debt is 124% more than the equity
The debt to equity has surged by 88% year-on-year and by 44% since the previous quarter
Minerva Neurosciences's equity has shrunk by 80% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.